Yes, of course, but let's be a little realistic here. Given your price-per-share valuation, at 4.82 billion shares outstanding Genta would only be worth $57.8 billion if you calculate $12pps. Good luck with that! Here is my take: In the short term Genta will reverse split and then release more shares thereby diluting current share holders. We are potentially looking at another 1.2-1.5 billion shares. The number of shares outstanding should stabilize at around 6 billion (or 120 million after 50:1 R/S). In the long term there will be no buyout (because it is not in the management's interest) and the stock will likely slide another 10-15% on dilution and R/S. However, IF the drug is approved by FDA, Genta's price per share will increase to approximately $0.25 - $0.40 (or $12.5 - $20.0 adjusted for 50:1 R/S) per share which will push the value of the company to $1.5 ~ $2.5 billion.
Qualle "Google Finance" |